CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
免疫效应细胞相关噬血细胞综合征（IEC-HS）作为弥漫大 B 细胞淋巴瘤（DLBCL）CAR-T 治疗后迟发性免疫介导毒性：一例病例报告
英文原题：Immune Effector Cell-associated Hemophagocytic Syndrome (IEC-HS) as a late immune-mediated toxicity after CAR-T therapy in Diffuse Large B-Cell Lymphoma (DLBCL): a case report.
查看英文原题
Immune Effector Cell-associated Hemophagocytic Syndrome (IEC-HS) as a late immune-mediated toxicity after CAR-T therapy in Diffuse Large B-Cell Lymphoma (DLBCL): a case report.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
嵌合抗原受体（CAR）T细胞疗法显著改善了复发/难治性弥漫性大B细胞淋巴瘤（DLBCL）患者的预后[1,2]。然而，免疫介导毒性仍是日益突出的临床挑战，尤其是迟发或少见表现。我们报告一例71岁女性患者，既往接受多线治疗的DLBCL患者在CAR-T 输注6个月后发生免疫效应细胞相关噬血综合征（IEC-HS），最终死亡。本病例凸显了CAR-T 相关毒性可能迟发，以及CAR-T 细胞持续存在可能参与维持失调免疫活化。
展开英文摘要原文
Chimeric antigen receptor (CAR) T-cell therapy has dramatically improved the prognosis of patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) [1,2].
However, immune-mediated toxicities represent a significant emerging clinical challenge, particularly those with late onset or uncommon presentations.
We report the case of a 71-year-old woman with heavily pretreated DLBCL who developed immune effector cell-associated hemophagocytic syndrome (IEC-HS) with a fatal outcome six months following CAR-T infusion. This case highlights the occurrence of late -onset CAR-T-related toxicities and the potential role of CAR-T cell persistence in sustaining dysregulated immune activation.
论文信息
- 作者
- Rincón-López S、García-Muñoz R、Atencio-Matos J、Pereda-Sainz O、Larreina-Pérez J、Campeny-Najara A、Pérez PH、Hernández-Pérez M
- 单位
- Universidad de La Rioja, Logroño, Spain. sorincon@unirioja.es.Spain
- 文献类型
- 病例报告
- 期刊
- Annals of hematology2026 Jun 26
- 原文标识
- PubMed 42360480 · DOI 10.1007/s00277-026-07105-x
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →